Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,844,118
  • Shares Outstanding, K 101,091
  • Annual Sales, $ 351,320 K
  • Annual Income, $ -7,230 K
  • 60-Month Beta 1.41
  • Price/Sales 37.97
  • Price/Cash Flow N/A
  • Price/Book 49.80
Trade NVCR with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.04
  • Number of Estimates 6
  • High Estimate 0.08
  • Low Estimate 0.01
  • Prior Year 0.02
  • Growth Rate Est. (year over year) +100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
102.06 +23.43%
on 09/24/20
140.89 -10.59%
on 10/14/20
+21.82 (+20.96%)
since 09/22/20
3-Month
64.91 +94.08%
on 07/24/20
140.89 -10.59%
on 10/14/20
+59.14 (+88.47%)
since 07/22/20
52-Week
53.40 +135.91%
on 03/23/20
140.89 -10.59%
on 10/14/20
+54.17 (+75.43%)
since 10/22/19

Most Recent Stories

More News
4 Overvalued Stocks to Avoid for the Rest of 2020

Valuations for stocks such as Datadog (DDOG), DraftKings (DKNG), NovoCure (NVCR), and Chegg (CHGG) look stretched. The company's current and expected financials fail to justify their valuations. Its best...

DDOG : 100.05 (-2.07%)
DKNG : 41.85 (+0.84%)
NVCR : 125.14 (-1.51%)
CHGG : 86.16 (+0.09%)
NVE Schedules Conference Call on Second-Quarter Results

NVE Corporation (Nasdaq: NVEC) announced that it plans to release its financial results for the quarter and six months ended September 30, 2020 on Wednesday, October 21, 2020 after the close of the Nasdaq...

NVCR : 125.14 (-1.51%)
NVEC : 47.79 (-1.18%)
Kroger, Hyatt Hotels, ResMed, LHC Group and NovoCure highlighted as Zacks Bull and Bear of the Day

Kroger, Hyatt Hotels, ResMed, LHC Group and NovoCure highlighted as Zacks Bull and Bear of the Day

RMD : 181.61 (+1.38%)
H : 57.90 (+4.49%)
KR : 32.17 (-3.48%)
LHCG : 221.00 (+1.38%)
NVCR : 125.14 (-1.51%)
3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic

Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.

MASI : 236.90 (+1.17%)
RMD : 181.61 (+1.38%)
ABT : 108.79 (+2.70%)
TMO : 481.74 (+2.77%)
LHCG : 221.00 (+1.38%)
NVCR : 125.14 (-1.51%)
Jabil, Harley-Davidson, TMO, LHCG and NovoCure as Zacks Bull and Bear of the Day

Jabil, Harley-Davidson, TMO, LHCG and NovoCure as Zacks Bull and Bear of the Day

JBL : 35.08 (+0.29%)
HOG : 29.73 (+1.88%)
TMO : 481.74 (+2.77%)
LHCG : 221.00 (+1.38%)
NVCR : 125.14 (-1.51%)
3 Growth-Focused MedTech Stocks to Buy Amid the COVID-19 Crisis

Here are three growth stocks from the MedTech space which have maintained stellar performance even during the pandemic-led market meltdown.

RMD : 181.61 (+1.38%)
TMO : 481.74 (+2.77%)
LHCG : 221.00 (+1.38%)
NVCR : 125.14 (-1.51%)
Is NovoCure (NVCR) Outperforming Other Medical Stocks This Year?

Is (NVCR) Outperforming Other Medical Stocks This Year?

NVCR : 125.14 (-1.51%)
Novocure to Report Third Quarter 2020 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2020 on Thursday, October 29, 2020, before the U.S. financial markets open. Novocure's management will...

NVCR : 125.14 (-1.51%)
Novocure to Host Virtual Research & Development Day

Novocure (NASDAQ: NVCR) announced today that it will host a virtual Research & Development Day for analysts and investors from 7:30 a.m. to 9:30 a.m. EDT on Thursday, November 12, 2020, to highlight progress...

NVCR : 125.14 (-1.51%)
Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community

Novocure (NASDAQ: NVCR) announced today initiatives to bring attention to Mesothelioma Awareness Day on September 26. In partnership with the Mesothelioma Applied Research Foundation, Novocure has arranged...

APLS : 33.39 (+1.80%)
NVCR : 125.14 (-1.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

2nd Resistance Point 137.14
1st Resistance Point 132.10
Last Price 125.14
1st Support Level 123.62
2nd Support Level 120.18

See More

52-Week High 140.89
Last Price 125.14
Fibonacci 61.8% 107.47
Fibonacci 50% 97.15
Fibonacci 38.2% 86.82
52-Week Low 53.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar